ZVRA Stock Forecast & Price Target

Zevra Therapeutics is supported by a durable U.S. MIPLYFFA launch that generated $30.2M in 2Q26 net sales and 184 cumulative prescription enrollment forms, with patient-finding efforts increasingly uncovering previously undiagnosed adult and pediatric NPC patients. Its commercial moat is strengthened by an integrated rare-disease infrastructure, 69% covered-life access, high persistence, and patent protection extending through 2041, while the market appears to underappreciate the larger ~900-patient U.S. prevalence opportunity versus the 300–350 already diagnosed pool. Financial flexibility is another key pillar, with $260.2M in cash and investments, no debt, and $39.7M in 2Q26 total revenue, giving management room to pursue European re-examination, maintain global EAP momentum, and develop celiprolol as a potential second franchise.

Zevra Therapeutics is facing a weaker fundamental profile because the updated financial assumptions and share count tied to the 2Q26 report point to softer near-term economics, while volatile non-French EAP reimbursements forced lower ROW/EAP revenue estimates. Commercial execution risk is elevated as a recent competitor approval could pressure demand for Miplyffa, reduce payer access, slow the launch ramp, and cap peak penetration and sales potential if safety or tolerability issues emerge. The company also carries meaningful regulatory, clinical, and balance-sheet risk, since pipeline failures, possible FDA or EMA setbacks, ongoing losses, and likely future capital needs all undermine long-term visibility.